Literature DB >> 20542988

Site-directed gene repair of the dystrophin gene mediated by PNA-ssODNs.

Refik Kayali1, Frederic Bury, McIver Ballard, Carmen Bertoni.   

Abstract

Permanent correction of gene defects is an appealing approach to the treatment of genetic disorders. The use of single-stranded oligodeoxynucleotides (ssODNs) has been demonstrated to induce single-point mutations in the dystrophin gene and to restore dystrophin expression in the skeletal muscle of models of Duchenne muscular dystrophy (DMD). Here we show that ssODNs made of peptide nucleic acids (PNA-ssODNs) can achieve gene repair frequencies more than 10-fold higher than those obtained using an older generation of targeting oligonucleotides. Correction was demonstrated in muscles cells isolated from mdx(5cv) mice and was stably inherited over time. Direct intramuscular injection of PNA-ssODNs targeting the mdx(5cv) mutation resulted in a significant increase in dystrophin-positive fibers when compared with muscles that received the ssODNs designed to correct the dystrophin gene but made of unmodified bases. Correction was demonstrated at both the mRNA and the DNA levels using quantitative PCR and was confirmed by direct sequencing of amplification products. Analysis at the protein level demonstrated expression of full-length dystrophin in vitro as well as in vivo. These results demonstrate that oligonucleotides promoting strand invasion in the DNA double helix can significantly enhance gene repair frequencies of the dystrophin gene. The use of PNA-ssODNs has important implications in terms of both efficacy and duration of the repair process in muscles and may have a role in advancing the treatment of DMD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20542988     DOI: 10.1093/hmg/ddq235

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  16 in total

Review 1.  Targeted gene therapies: tools, applications, optimization.

Authors:  Olivier Humbert; Luther Davis; Nancy Maizels
Journal:  Crit Rev Biochem Mol Biol       Date:  2012 May-Jun       Impact factor: 8.250

2.  Purloined mechanisms of bacterial immunity can cure muscular dystrophy.

Authors:  James G Tidball; Carmen Bertoni
Journal:  Cell Metab       Date:  2014-12-02       Impact factor: 27.287

3.  Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy.

Authors:  Refik Kayali; Jin-Mo Ku; Gregory Khitrov; Michael E Jung; Olga Prikhodko; Carmen Bertoni
Journal:  Hum Mol Genet       Date:  2012-06-12       Impact factor: 6.150

4.  A high-content, high-throughput siRNA screen identifies cyclin D2 as a potent regulator of muscle progenitor cell fusion and a target to enhance muscle regeneration.

Authors:  Michael V Khanjyan; Jonathan Yang; Refik Kayali; Thomas Caldwell; Carmen Bertoni
Journal:  Hum Mol Genet       Date:  2013-04-23       Impact factor: 6.150

Review 5.  Gene and cell-mediated therapies for muscular dystrophy.

Authors:  Patryk Konieczny; Kristy Swiderski; Jeffrey S Chamberlain
Journal:  Muscle Nerve       Date:  2013-03-29       Impact factor: 3.217

6.  Repair of single-point mutations by polypurine reverse Hoogsteen hairpins.

Authors:  Anna Solé; Xenia Villalobos; Carlos J Ciudad; Véronique Noé
Journal:  Hum Gene Ther Methods       Date:  2014-10-14       Impact factor: 2.396

Review 7.  Oligonucleotide Therapies: The Past and the Present.

Authors:  Karin E Lundin; Olof Gissberg; C I Edvard Smith
Journal:  Hum Gene Ther       Date:  2015-08-03       Impact factor: 5.695

Review 8.  Emerging gene editing strategies for Duchenne muscular dystrophy targeting stem cells.

Authors:  Carmen Bertoni
Journal:  Front Physiol       Date:  2014-04-21       Impact factor: 4.566

9.  Persistent dystrophin protein restoration 90 days after a course of intraperitoneally administered naked 2'OMePS AON and ZM2 NP-AON complexes in mdx mice.

Authors:  Elena Bassi; Sofia Falzarano; Marina Fabris; Francesca Gualandi; Luciano Merlini; Gaetano Vattemi; Daniela Perrone; Elena Marchesi; Patrizia Sabatelli; Katia Sparnacci; Michele Laus; Paolo Bonaldo; Paola Rimessi; Paola Braghetta; Alessandra Ferlini
Journal:  J Biomed Biotechnol       Date:  2012-10-02

10.  Engineered DNA plasmid reduces immunity to dystrophin while improving muscle force in a model of gene therapy of Duchenne dystrophy.

Authors:  Peggy P Ho; Lauren J Lahey; Foteini Mourkioti; Peggy E Kraft; Antonio Filareto; Moritz Brandt; Klas E G Magnusson; Eric E Finn; Jeffrey S Chamberlain; William H Robinson; Helen M Blau; Lawrence Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-04       Impact factor: 12.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.